The Products Everyone Sells and Nobody Understands
Walk into any legal cannabis market or wellness store and you'll find them by the shelf-full: balms, salves, bath bombs, transdermal patches, and an ocean of CBD products — oils, gummies, creams, pet treats, sparkling water — promising relief for pain, inflammation, anxiety, sleep, and skin. The CBD market alone grew into a multibillion-dollar industry faster than any supplement in history, outpacing the science by a comfortable margin. Meanwhile the actual evidence sits in a genuinely interesting place: real pharmacology, real therapeutic effects in specific domains, buried under marketing claims that outrun it by miles. Sorting the supported from the sold is this post's job.
Topicals: The Plausible Middle
Cannabis topicals — products applied to skin — occupy a pharmacologically sensible space. The skin has endocannabinoid receptors (CB1 and CB2) involved in inflammation, pain signaling, and itch; topical cannabinoids can engage these locally without meaningful systemic absorption, which is why topicals are popular for arthritis aches, muscle soreness, and neuropathic pain conditions like shingles after-effects. The honest evidence picture: small trials and a growing clinical literature support genuine local effects for certain conditions — a notable randomized trial of topical CBD for hand osteoarthritis and psoriatic arthritis showed measurable pain improvement, and smaller studies of topical cannabinoids for peripheral neuropathy pain show signals consistent with local CB engagement. No intoxication, minimal systemic exposure, a benign side-effect profile.
The limits deserve equal weight: topicals don't penetrate deeply enough to treat joint interiors or spinal problems directly (the arthritis findings likely run through skin-level and neural mechanisms), the market's dosing is wildly unstandardized, and the placebo contribution in pain trials of topical anything is large. Topicals are best understood as a reasonable, low-risk option for localized symptoms with a plausible mechanism and preliminary supporting data — not as the systemic medicine the labels imply.
Transdermal Patches: The Different Animal
Worth distinguishing from topicals: transdermal patches are designed for systemic absorption — cannabinoids delivered through the skin into the bloodstream over hours, bypassing digestion entirely. They work (pharmaceutically, patches are a proven delivery technology), they produce systemic effects including intoxication at THC doses, and they carry the full interaction and impairment considerations of any systemic cannabinoid route. A "THC patch" is not a balm; it's slow-release oral dosing wearing a different costume.
CBD: The Real Evidence
CBD is the rare supplement with genuine pharmaceutical legitimacy — the FDA approved Epidiolex, a purified CBD, for two severe pediatric epilepsy syndromes, based on randomized trials showing dramatic seizure reduction. That's real medicine, at real doses (hundreds of milligrams daily), in a specific population. What does that imply for the wellness market? Carefully.
What's supported: seizure reduction in specific syndromes (prescription-only, at high doses); modest evidence for anxiety in some trial contexts (social anxiety study data, early generalized-anxiety findings) at doses far above typical retail products; anti-inflammatory mechanisms with early clinical signals; and reasonable evidence for certain pain conditions as an adjunct. The enzyme interaction profile — CBD's potent CYP3A4 and CYP2C19 inhibition — is real pharmacology covered in this series' CYP post, and it matters at exactly the doses wellness marketing encourages.
What's oversold: nearly everything on a typical CBD label. The sleep claims, the inflammation claims, the "recovery" positioning of athlete marketing, the pet products, the beverages with five milligrams per can. The dose problem is structural: most retail CBD products contain 10–25mg per serving, while the trial evidence for anxiety and related effects typically used 300–600mg. A consumer paying premium prices for a gummy is buying the anecdote of a dose, not the studied one. Add the quality control problem — independent testing has repeatedly found CBD products with wildly inaccurate labeled content, unlabeled THC (a real problem for anyone drug-tested or THC-sensitive), and contaminants — and the market's honest summary is: real molecule, real effects at real doses, chaotic delivery system, and marketing that wouldn't survive contact with the evidence it claims.
The Drug-Testing Landmine
Two practical hazards deserve their own air. First, CBD products and drug tests: unlabeled THC in "CBD-only" products has produced failed drug tests, lost jobs, and legal problems for users who believed the label — an unavoidable risk in an unregulated product category where the FDA has explicitly declined to provide a regulatory framework. Anyone subject to testing should treat all CBD products as potential THC exposure. Second, the liver interaction front: at the high doses some users take, CBD's enzyme inhibition becomes clinically meaningful (the warfarin, clopidogrel, and immunosuppressant interactions of the CYP post apply in full), which turns a "harmless supplement" into a medication-management problem for a large and unsuspecting population.
Practical Guidance
For the consumer navigating this shelf: treat topicals as a reasonable, low-risk experiment for localized pain with modest expectations; treat transdermal THC as real systemic dosing; treat CBD marketing claims with the skepticism the evidence earns (real molecule, wrong doses, weak regulation); buy only from products with verifiable third-party Certificates of Analysis covering cannabinoid content and contaminants; keep your pharmacist in the loop if you take any medication metabolized by CYP3A4 or CYP2C19; and never let "it's just CBD" mean "it can't interact with anything." The body doesn't read the label. The liver reads the molecule.
The Regulatory Vacuum
The deepest problem in the topicals-and-CBD space isn't any single product — it's that no one is in charge of the category. The FDA has explicitly declined to establish a regulatory framework for CBD in supplements and foods, leaving the market in a permanent gray zone where quality control is voluntary, claims are self-policed, and the testing that would protect consumers exists only where states or reputable manufacturers impose it on themselves. The comparison to the legal cannabis market is instructive: state-regulated cannabis products must meet testing and labeling standards that CBD products, ironically, escape precisely because they're sold as not cannabis. A consumer navigating this landscape owes themselves a single discipline that compensates for the missing regulator: never buy a cannabinoid product without a current, verifiable Certificate of Analysis from an independent laboratory, and treat the absence of one as the answer to whether the product deserves your money.
The Bottom Line (Revisited)
For the consumer navigating this shelf: treat topicals as a reasonable, low-risk experiment for localized pain with modest expectations; treat transdermal THC as real systemic dosing; treat CBD marketing claims with the skepticism the evidence earns — real molecule, wrong doses, weak regulation; buy only from products with verifiable third-party Certificates of Analysis covering cannabinoid content and contaminants; keep your pharmacist in the loop if you take any medication metabolized by CYP3A4 or CYP2C19; and never let "it's just CBD" mean "it can't interact with anything." The body doesn't read the label. The liver reads the molecule.
